Datasheet

Frequently asked questions (FAQs) on Bundibugyo Virus Disease vaccines and therapeutics

World Health Organization (WHO), WHO Regional Office for Africa (AFRO)

This FAQ provides key information on vaccines and therapeutics for Bundibugyo virus disease (BVD), including current evidence, ongoing research, WHO recommendations, and key messages for national authorities and communities.

This document will be updated as new information becomes available.

Authors

Languages

Publication year

2026

Type

Datasheet

Categories

Diseases

Countries

Organisations

ebola-BDBV

This resource appears in the following Hot Topic page:

The resource is included in the following table:

TitleAuthorYearTypeLanguage
WHO emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo virus disease outbreaks, 28 May 2026World Health Organization (WHO)2026GuidanceEnglish
Frequently asked questions (FAQs) on Bundibugyo Virus Disease vaccines and therapeuticsWorld Health Organization (WHO), WHO Regional Office for Africa (AFRO)2026DatasheetEnglish, French
WHO Technical Advisory Group on Candidate Vaccine Prioritization Meeting report, 19 and 25 May 2026World Health Organization (WHO)2026ReportEnglish
GNN webinar: Updates on existing and pipeline Ebola vaccinesHelen Rees, Reena Doshi, Alejandro Costa, Melanie Marti, Pierre Gsell2026WebinarEnglish
WHO target product profile for Bundibugyo virus disease vaccinesWorld Health Organization (WHO)2026ReportEnglish
WHO Technical Advisory Group on candidate vaccine prioritization (TAG-CVP) for BVD candidate vaccine prioritization (TAG-CVP) meeting report, 31 July 2026World Health Organization (WHO)2026ReportEnglish
Orientations d'urgence de l'OMS sur l'utilisation du vaccin homologué contre Ebola lors des flambées de maladie à virus BundibugyoWorld Health Organization (WHO)2026GuidanceFrench

Added by: Reena Doshi

Added on: 2026-06-09 09:45:57

Hits: 465

Links

Uploaded file

FAQ_BVD_VT.pdf

Click to Download

Report an issue

Add resource